Table 3.

Risk of COVID-19-Related Hospitalization or Emergency Department Visit Within 30 Days of SARS-CoV-2-Positive Viral Test

	Unadjusted		Adjusted
	OR	[95% CI]	OR	[95% CI]
(Intercept)			0.05	[0.02–0.12]
Gender
Female	1.00	[0.54–1.93]	0.88	[0.44–1.78]
Male	Reference		Reference
Age, y
≤64	Reference		Reference
>65	1.06	[0.57–1.99]	2.10	[0.97–4.77]
Race
Black	1.60	[0.23–5.90]	1.2	[0.17–5.12]
White	Reference		Reference
Other	0.36	[0.02–1.71]	0.35	[0.02–1.79]
Unknown	0.29	[0.01–1.35]	0.54	[0.03–2.87]
Ethnicity
Hispanic	1.50	[0.80–2.78]	1.66	[0.84–3.32]
Non-Hispanic	Reference		Reference
Body mass index
<30 kg/m2	Reference		Reference
≥30–<35 kg/m2	1.61	[0.67–3.46]	1.98	[0.76–4.76]
≥35 kg/m2	4.95	[2.21–10.5]*	6.44	[2.48–16.71]*
Comorbidities
Hypertension	2.22	[1.19–4.19]*	1.37	[0.67–2.81]
Chronic kidney disease	1.61	[0.36–4.89]	1.15	[0.25–3.79]
Cardiovascular disease	1.73	[0.78–3.54]	1.07	[0.45–2.40]
mAb treatment	0.14	[0.05–0.34]*	0.18	[0.06–0.44]*

Abbreviations: COVID-19, coronavirus disease 2019; mAb, monoclonal antibody; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

*P < .05.